A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

M. Aglietta1*, C. Barone2, M. B. Sawyer3, M. J. Moore4, W. H. Miller, Jr5, C. Bagala2, F. Colombi1, C. Cagnazzo1, L. Gioeni1, E. Wang6, B. Huang6, K. D. Fly6 & F. Leone1 Department of Medical Oncology, University of Torino, Candiolo Cancer Institute–FPO, IRCCS, Turin; Department of Medical Oncology, Catholic University of the Sacred Heart, Rome, Italy; Department of Oncology, University of Alberta, Edmonton; Division of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto; Department of Oncology, McGill University, Montreal, Canada; Pfizer Oncology Global Research and Development, Groton, USA